Alnylam Competitors and Similar CompaniesClear all

Alnylam's competitors and similar companies include Reata Pharmaceuticals, Celyad, Moderna, CureVac, Regulus Therapeutics and Ionis Pharmaceuticals.
Alnylam
Alnylam
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
Reata Pharmaceuticals
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.
Celyad
Celyad
Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.
Moderna
Moderna
Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine.
CureVac
CureVac
CureVac is a biotechnology company offering messenger RNA (mRNA) technology.
Regulus Therapeutics
Regulus Therapeutics
Regulus Therapeutics is a biopharmaceutical company involved in the R&D of high-impact medicines based on microRNAs.
Ionis Pharmaceuticals
Ionis Pharmaceuticals
Ionis Pharmaceuticals (formerly known as Isis Pharmaceuticals) is a company that discovers and develops RNA-targeted therapeutics.
Founding Date
Founding Date
2002
Founding Date
2002
Founding Date
2007
Founding Date
2010
Founding Date
2000
Founding Date
2007
Founding Date
1989
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Cambridge, US HQ
Paris, FR
Milan, IT
Tokyo, JP
Amsterdam, NL
Stockholm, SE
Zug, CH
see more
Locations
Plano, US HQ
Irving, US
Plano, US
Locations
Mont-Saint-Guibert, BE HQ
New York, US
Locations
Cambridge, US HQ
Melbourne, AU
Paris, FR
München, DE
Tokyo, JP
Seoul, KR
Warszawa, PL
see more
Locations
Tübingen, DE HQ
Ottignies Louvain La Neuve, BE
Wiesbaden, DE
Amsterdam, NL
Basel, CH
Boston, US
Locations
San Diego, US HQ
Locations
Carlsbad, US HQ
Employees
Employees
1,32324% increase
Employees
3217% decrease
Employees
1751% decrease
Employees
5,60044% increase
Employees
999
Employees
2462% decrease
Employees
92716% increase
Valuation ($)
Valuation ($)
35.8 b
Valuation ($)
6.6 b
Valuation ($)
N/A
Valuation ($)
23.1 b
Valuation ($)
643.8 m
Valuation ($)
105.4 m
Valuation ($)
6.2 b

Financial

Revenue (est.)
Revenue (est.)
$1.8b (FY, 2023)
Revenue (est.)
$2.2m (FY, 2022)
Revenue (est.)
€102k (FY, 2023)
Revenue (est.)
$6.8b (FY, 2023)
Revenue (est.)
€53.8m (FY, 2023)
Revenue (est.)
N/A
Revenue (est.)
$787.6m (FY, 2023)
Cost of goods
Cost of goods
$268.2m (FY, 2023)
Cost of goods
N/A
Cost of goods
€69k (FY, 2023)
Cost of goods
$4.7b (FY, 2023)
Cost of goods
€64.3m (FY, 2023)
Cost of goods
N/A
Cost of goods
$9.1m (FY, 2023)
Gross profit
Gross profit
$1.6b (FY, 2023)
Gross profit
N/A
Gross profit
€1.4m (FY, 2023)
Gross profit
$2.2b (FY, 2023)
Gross profit
(€2.6m) (FY, 2023)
Gross profit
N/A
Gross profit
$778.5m (FY, 2023)
Net income
Net income
($440.2m) (FY, 2023)
Net income
($311.9m) (FY, 2022)
Net income
(€8.4m) (FY, 2023)
Net income
($4.7b) (FY, 2023)
Net income
(€260.2m) (FY, 2023)
Net income
($30m) (FY, 2023)
Net income
($366.3m) (FY, 2023)

Operating

Patent Applications
Patent Applications
N/A
Patent Applications
N/A
Patent Applications
N/A
Patent Applications
430 (FY, 2021)
Patent Applications
500 (Mar, 2020)
Patent Applications
N/A
Patent Applications
N/A
Patents Issued
Patents Issued
N/A
Patents Issued
240 (FY, 2016)
Patents Issued
N/A
Patents Issued
270 (FY, 2020)
Patents Issued
233 (May, 2020)
Patents Issued
300 (FY, 2016)
Patents Issued
N/A
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
2 (FY, 2016)
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
3 (May, 2020)
Phase I Trials Products
N/A
Phase I Trials Products
1 (FY, 2023)
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
4 (FY, 2016)
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
13 (FY, 2023)
Phase III Trials Products
Phase III Trials Products
N/A
Phase III Trials Products
1 (FY, 2016)
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
N/A
Phase III Trials Products
9 (FY, 2023)

Funding

Total funding raised
Total funding raised
$ 1.5b
Total funding raised
$ 468.9m
Total funding raised
N/A
Total funding raised
$ 1.8b
Total funding raised
$ 1.1b
Total funding raised
$ 10m
Total funding raised
N/A
For sources of this data, please see the company profile

View Company Profiles

Reata Pharmaceuticals
HQ
Plano, US
Employees
321↓ 7% decrease

Reata Pharmaceuticals is a biopharmaceutical company that develops therapeutics for patients with serious or life-threatening diseases.

View company
Celyad
HQ
Mont-Saint-Guibert, BE
Employees
17

Celyad is a biopharmaceutical company focused on the discovery and development of regenerative and protective therapies in cardiology and oncology.

View company
Moderna
HQ
Cambridge, US
Employees
5,600↑ 44% increase

Moderna (formerly Moderna Therapeutics) is a biotechnology company focused on messenger RNA (mRNA) medicine.

View company
CureVac
HQ
Tübingen, DE
Employees
999

CureVac is a biotechnology company offering messenger RNA (mRNA) technology.

View company